From the commercial point of view the aesthetics of large luxury yachts has the same importance of their technical performances and reliability. In this perspective the first impact that a new construction can exert on a potential owner takes place through the overall appearance of the hull and superstructures. The hull colour, in particular,...
-
2017 (v1)PublicationUploaded on: April 14, 2023
-
2015 (v1)Publication
At the end of structure assembling sides of yacht hulls are usually affected by bump and hollows coming from welding plates each other and plates to frames. This defect, normally tolerated on merchant ships, cannot be accepted on yachts for which the external surface must be smooth and glossy. In case of GRP vessels surface finishing comes from...
Uploaded on: April 14, 2023 -
2022 (v1)Publication
Background: The number of patients using palliative care services, particularly residential hospices, is increasing. Policymakers are urging these services to reflect on the most effective organizational strategies for meeting patients' complex care needs. Aim: To analyze the predictive power of staffing, structure and process indicators...
Uploaded on: February 4, 2024 -
2013 (v1)Publication
Objectives: To explore the durability of three first-line tenofovir/emtricitabine-based regimens in combination with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in HIV-1-infected patients. Patients and methods: A retrospective, longitudinal, multicentre analysis of adult patients enrolled in the Antiretroviral Resistance Cohort...
Uploaded on: April 14, 2023 -
2019 (v1)Publication
Background: Nivolumab was the first immune checkpoint inhibitor approved for previously treated advanced non–small cell lung cancer (NSCLC). Before its introduction in the market, nivolumab was made available to NSCLC patients through an expanded access program (EAP). Here we present the Italian cohort of patients with non-squamous NSCLC...
Uploaded on: April 14, 2023 -
2021 (v1)Publication
Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination...
Uploaded on: April 14, 2023 -
2023 (v1)Publication
Background: Following the increased survival of patients with metastatic melanoma thanks to immunotherapy and targeted therapy, neoadjuvant approaches are being investigated to address the unmet needs of unresponsive and intolerant patients. We aim to investigate the efficacy of neoadjuvant plus adjuvant combined or sequenced vemurafenib,...
Uploaded on: July 3, 2024 -
2019 (v1)Publication
Objectives: Considering the frequent expression of somatostatine receptors, we designed the G04.2011 trial to investigate the efficacy of the somatostatine analogue lanreotide in maintenance for SCLC patients after response to standard treatment. Materials and Methods: A multicenter, randomized, phase 3 trial was conducted in SCLC expressing...
Uploaded on: April 14, 2023 -
2020 (v1)Publication
Introduction: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system with an underlying immune-mediated and inflammatory pathogenesis. Innate immunity, in addition to the adaptive immune system, plays a relevant role in MS pathogenesis. It represents the immediate non-specific defense against infections through the...
Uploaded on: April 14, 2023 -
2023 (v1)Publication
Background: Metastatic renal cell carcinoma (mRCC) treatment is still largely based on TKI use. Treatment adjustment due to toxicities is often needed. The aim of the present study was to determine the impact of treatment modifications on the outcome of mRCC patients treated with cabozantinib or pazopanib. Research design and methods: This...
Uploaded on: February 6, 2024 -
2023 (v1)Publication
PURPOSELimited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma.METHODSSECOMBIT is a randomized, three-arm, noncomparative phase II trial (ClinicalTrials.gov identifier: NCT02631447). Patients with untreated, metastatic BRAFV600-mutant melanoma from 37 sites in nine...
Uploaded on: July 3, 2024 -
2023 (v1)Publication
Introduction: The CheckMate 238 randomised study demonstrated the relevant benefit in terms of recurrence-free survival (RFS) of nivolumab versus ipilimumab in resected stage IIIB-C or IV melanoma patients with a tolerable safety profile. Materials and methods: From November 2018 to June 2019, 611 patients with stage III and IV resected...
Uploaded on: July 3, 2024 -
2022 (v1)Publication
Background: The Meet-URO score allowed a more accurate prognostication than the International Metastatic RCC Database Consortium (IMDC) for patients with pre-treated metastatic renal cell carcinoma (mRCC) by adding the pre-treatment neutrophil-to-lymphocyte ratio and presence of bone metastases. Materials and methods: A post hoc analysis was...
Uploaded on: February 14, 2024